Search research articles
Contact Us
Filters
Showing results (51-60 of 56) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 56 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 1993
Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias
M A Schwartz, D R Lovett, A Redner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 1, 1992
PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma
S M Larson, K S Pentlow, N D Volkow, et al.
Blood
|
April 1, 1994
A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity
P C Caron, J G Jurcic, A M Scott, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 1, 1996
Quantitative imaging of iodine-124 with PET
K S Pentlow, M C Graham, R M Lambrecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 26, 1998
Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma
C R Divgi, N H Bander, A M Scott, et al.
Journal of Environmental Monitoring : JEM
|
May 21, 2004
Development of an ombrotrophic peat bog (low ash) reference material for the determination of elemental concentrations
C Yafa, J G Farmer, M C Graham, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 56) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 56 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 1993
Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias
M A Schwartz, D R Lovett, A Redner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 1, 1992
PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma
S M Larson, K S Pentlow, N D Volkow, et al.
Blood
|
April 1, 1994
A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity
P C Caron, J G Jurcic, A M Scott, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 1, 1996
Quantitative imaging of iodine-124 with PET
K S Pentlow, M C Graham, R M Lambrecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 26, 1998
Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma
C R Divgi, N H Bander, A M Scott, et al.
Journal of Environmental Monitoring : JEM
|
May 21, 2004
Development of an ombrotrophic peat bog (low ash) reference material for the determination of elemental concentrations
C Yafa, J G Farmer, M C Graham, et al.
Page
of 6